Akeso, Inc. (HKG:9926)

Market Cap	100.13B -19.4%
Revenue (ttm)	3.98B +37.4%
Net Income	-1.12B
EPS	-1.22
Shares Out	921.14M
PE Ratio	n/a
Forward PE	138.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,106,342
Open	102.10
Previous Close	106.30
Day's Range	101.00 - 109.90
52-Week Range	80.20 - 156.00
Beta	0.02
Analysts	Strong Buy
Price Target	155.54 (+43.09%)
Est. Earnings	Nov 27, 2026

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 4,082
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9926

Financial Performance

In 2025, Akeso's revenue was 3.06 billion, an increase of 43.90% compared to the previous year's 2.12 billion. Losses were -1.11 billion, 116.3% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 24 analysts, the average rating for 9926 stock is "Strong Buy." The 12-month stock price target is $155.54, which is an increase of 43.09% from the latest price.

Price Target

$155.54

(43.09% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error